Management of type 2 diabetes mellitus and cardiovascular risk -: Lessons from intervention trials

被引:34
|
作者
Yki-Järvinen, H [1 ]
机构
[1] Univ Helsinki, Dept Med, Helsinki 00029, Finland
关键词
D O I
10.2165/00003495-200060050-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although the diagnosis of type 2 (noninsulin-dependent) diabetes mellitus is made when blood glucose levels exceed values which increase the risk of microvascular complications, macrovascular disease is the major complication of type 2 diabetes mellitus. Both epidemiological and prospective data have demonstrated that treatment of hyperglycaemia is markedly effective in reducing the risk of microvascular disease but is less potent in reducing that of myocardial infarction, stroke and peripheral Vascular disease. Treatment of other cardiovascular risk factors, although by definition less prevalent than hyperglycaemia, appears to be more effective in preventing macrovascular disease than treatment of hyperglycaemia. In recent years, data from intervention trials have suggested that greater benefits with respect to the prevention of macrovascular disease can be achieved by effective treatment of hypertension and hypercholesterolaemia, and by the use of small doses of aspirin (acetylsalicylic acid) than by treating hyperglycaemia alone. On the other hand, the UK Prospective Diabetes Study (UKPDS), which examined the impact of intensive glucose and blood pressure (BP) control on micro- and macrovascular complications,is the only intervention trial to include only patients with type 2 diabetes mellitus. The UKPDS data, the epidemic increase in the number of patients with type 2 diabetes mellitus and their high cardiovascular risk have, however, initiated several new trials addressing, in particular, the possible benefits of treatment of the most common form of dyslipidaemia (high serum triglyceride and low high density lipoprotein cholesterol levels) in these patients. Type 2 diabetes mellitus is thus a disease associated with a high vascular risk, where the majority of patients need, and are likely to benefit from, pharmacological treatment of several cardiovascular risk factors provided treatment targets have not been achieved by life-style modification.
引用
收藏
页码:975 / 983
页数:9
相关论文
共 50 条
  • [31] Cardiovascular Risk in Type 1 Diabetes Mellitus
    Schofield, Jonathan
    Ho, Jan
    Soran, Handrean
    DIABETES THERAPY, 2019, 10 (03) : 773 - 789
  • [32] Type 1 diabetes mellitus and cardiovascular risk
    Jose Chillaron, Juan
    Francisco Cano, Juan
    Pedro-Botet, Juan
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2008, 20 (05): : 210 - 217
  • [33] Cardiovascular Risk in Type 1 Diabetes Mellitus
    Jonathan Schofield
    Jan Ho
    Handrean Soran
    Diabetes Therapy, 2019, 10 : 773 - 789
  • [34] Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies
    Mazzone, Theodore
    Chait, Alan
    Plutzky, Jorge
    LANCET, 2008, 371 (9626): : 1800 - 1809
  • [35] Cardiovascular Risk in Children and Adolescents with Type 1 and Type 2 Diabetes Mellitus
    Magge S.N.
    Current Cardiovascular Risk Reports, 2012, 6 (6) : 591 - 600
  • [36] The impact of the UKPDS Risk Engine on cardiovascular risk management in patients with type 2 diabetes mellitus in general practice
    Van den Donk, M.
    Wind, A. E.
    Gorter, K. J.
    Rutten, G. E. H.
    DIABETOLOGIA, 2011, 54 : S404 - S404
  • [37] Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
    Schernthaner, Guntram
    Jarvis, Sarah
    Lotan, Chaim
    Prazny, Martin
    Wanner, Christoph
    Wascher, Thomas C.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 69 - 79
  • [38] Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
    Lincoff, A. Michael
    Wolski, Kathy
    Nicholls, Stephen J.
    Nissen, Steven E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (10): : 1180 - 1188
  • [39] Cardiovascular disease in type 2 diabetes mellitus - Current management guidelines
    Mooradian, AD
    ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (01) : 33 - 40
  • [40] Cardiovascular risk in patients with newly diagnosed type 2 diabetes mellitus
    Fuadal-Saraj
    McAteer, S
    Galvin, J
    Keelan, E
    Fitzgerald, D
    Cawood, T
    Sreenan, SK
    DIABETES, 2005, 54 : A172 - A172